Literature DB >> 17483295

In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma.

Laurent Knoops1, Rick Haas, Sanne de Kemp, Donné Majoor, Annegien Broeks, Eric Eldering, Jan Paul de Boer, Marcel Verheij, Conny van Ostrom, Annemieke de Vries, Laura van't Veer, Daphne de Jong.   

Abstract

Very low-dose irradiation (2 x 2 Gy) is a new, effective, and safe local treatment for follicular lymphoma. To understand the biologic mechanisms of this extremely effective response, we compared by microarray the gene-expression profile of patients' biopsies taken before and after radiation. In all patients, a major and consistent induction of p53 target genes was seen. p53 targets involved in cell-cycle arrest and apoptosis showed the same mode of regulation, indicating that, in vivo, both are activated simultaneously. p53 up-regulation and p53-mediated proliferation arrest and apoptosis were substantiated using immunohistochemistry, with activation of both the intrinsic and the extrinsic apoptotic pathways. The other induced genes revealed a whole set of biologically meaningful genes related to macrophage activation and TH1 immune response. Immunohistochemical analysis suggested a specific activation or differentiation of resident macrophages by apoptotic cells. These biologic insights are important arguments to advocate the use of low-dose radiotherapy as an effective palliative treatment for follicular lymphoma. Moreover, this study is the first in vivo report of the radiation-induced p53 apoptotic response in patients and suggests that this apoptotic response is not immunologically silent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483295     DOI: 10.1182/blood-2007-01-067579

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Radiotherapy of indolent orbital lymphomas : Two radiation concepts.

Authors:  Laila König; Robert Stade; Juliane Rieber; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2016-05-09       Impact factor: 3.621

2.  Functional Genomics and a New Era in Radiation Biology and Oncology.

Authors:  Sally A Amundson
Journal:  Bioscience       Date:  2008-06-01       Impact factor: 8.589

3.  Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data.

Authors:  Ahmed Essaghir; Federica Toffalini; Laurent Knoops; Anders Kallin; Jacques van Helden; Jean-Baptiste Demoulin
Journal:  Nucleic Acids Res       Date:  2010-03-09       Impact factor: 16.971

4.  CCancer: a bird's eye view on gene lists reported in cancer-related studies.

Authors:  Sabine Dietmann; Wanseon Lee; Philip Wong; Igor Rodchenkov; Alexey V Antonov
Journal:  Nucleic Acids Res       Date:  2010-06-06       Impact factor: 16.971

Review 5.  Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?

Authors:  Lena Specht
Journal:  Curr Treat Options Oncol       Date:  2016-01

6.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

Authors:  Derville O'Shea; Ciarán O'Riain; Claire Taylor; Rachel Waters; Emanuela Carlotti; Finlay Macdougall; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Erlend B Smeland; Nathalie Johnson; Elias Campo; Timothy C Greiner; Wing C Chan; Randy D Gascoyne; George Wright; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

7.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

8.  Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas.

Authors:  Laila König; Juliane Hörner-Rieber; Denise Bernhardt; Adriane Hommertgen; Stefan Rieken; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

9.  The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma.

Authors:  Amy S Kimball; Tonya J Webb
Journal:  Mol Cell Pharmacol       Date:  2013-01-01

10.  Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study.

Authors:  Michael J Groves; Stephanie F Maccallum; Michael T Boylan; Sally Haydock; Joan Cunningham; Keith Gelly; Duncan Gowans; Ron Kerr; Philip J Coates; Sudhir Tauro
Journal:  J Cancer       Date:  2012-08-24       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.